Emerging concepts in liquid biopsies

BMC Medicine

Review

Samantha Perakis¹  Michael R. Speicher² 

[1] Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/8, A-8010, Graz, Austria;Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/8, A-8010, Graz, Austria;BioTechMed, Graz, Austria;

关键词: Cell-free DNA;    Circulating tumor DNA;    Circulating tumor cells;    Liquid biopsy;    Disease monitoring;    Precision medicine;   

DOI  :  10.1186/s12916-017-0840-6

 received in 2016-12-19, accepted in 2017-03-22,  发布年份 2017

来源: Springer

【 摘 要 】

Characterizing and monitoring tumor genomes with blood samples could achieve significant improvements in precision medicine. As tumors shed parts of themselves into the circulation, analyses of circulating tumor cells, circulating tumor DNA, and tumor-derived exosomes, often referred to as “liquid biopsies”, may enable tumor genome characterization by minimally invasive means. Indeed, multiple studies have described how molecular information about parent tumors can be extracted from these components. Here, we briefly summarize current technologies and then elaborate on emerging novel concepts that may further propel the field. We address normal and detectable mutation levels in the context of our current knowledge regarding the gradual accumulation of mutations during aging and in light of technological limitations. Finally, we discuss whether liquid biopsies are ready to be used in routine clinical practice.

【 授权许可】

CC BY   
© The Author(s). 2017